HC Wainwright Brokers Boost Earnings Estimates for SLNO

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for shares of Soleno Therapeutics in a research note issued on Friday, May 23rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.17 for the quarter, up from their previous forecast of $0.16. HC Wainwright currently has a "Buy" rating and a $100.00 target price on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics' Q3 2026 earnings at $0.41 EPS and FY2026 earnings at $1.24 EPS.

Other equities research analysts also recently issued reports about the company. Stifel Nicolaus increased their price target on Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a report on Friday, March 28th. Guggenheim increased their price target on Soleno Therapeutics from $81.00 to $97.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Piper Sandler increased their price target on Soleno Therapeutics from $93.00 to $145.00 and gave the stock an "overweight" rating in a report on Thursday, April 24th. Robert W. Baird increased their price target on Soleno Therapeutics from $102.00 to $105.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Finally, Lifesci Capital upgraded Soleno Therapeutics to a "strong-buy" rating in a report on Tuesday, February 4th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $106.78.

Soleno Therapeutics Trading Down 0.6%

Shares of NASDAQ SLNO traded down $0.49 during midday trading on Monday, hitting $75.77. The company's stock had a trading volume of 769,937 shares, compared to its average volume of 748,448. The business's 50 day moving average is $70.00 and its two-hundred day moving average is $55.98. Soleno Therapeutics has a 12-month low of $36.93 and a 12-month high of $80.99. The firm has a market cap of $3.82 billion, a P/E ratio of -22.82 and a beta of -2.67.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.19.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc grew its stake in Soleno Therapeutics by 9.2% during the 4th quarter. Legal & General Group Plc now owns 23,471 shares of the company's stock valued at $1,055,000 after purchasing an additional 1,983 shares during the last quarter. Barclays PLC grew its stake in Soleno Therapeutics by 149.3% during the 3rd quarter. Barclays PLC now owns 52,545 shares of the company's stock valued at $2,652,000 after purchasing an additional 31,467 shares during the last quarter. Emerald Advisers LLC grew its stake in Soleno Therapeutics by 85.4% during the 4th quarter. Emerald Advisers LLC now owns 580,919 shares of the company's stock valued at $26,112,000 after purchasing an additional 267,585 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Soleno Therapeutics by 13.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 217,550 shares of the company's stock valued at $9,779,000 after purchasing an additional 24,953 shares during the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Soleno Therapeutics by 47.0% in the 4th quarter. Sei Investments Co. now owns 16,444 shares of the company's stock valued at $739,000 after buying an additional 5,258 shares during the period. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Patricia C. Hirano sold 128,653 shares of the business's stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $68.32, for a total transaction of $8,789,572.96. Following the transaction, the insider now directly owns 55,789 shares in the company, valued at $3,811,504.48. The trade was a 69.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bhatnagar Anish sold 699,095 shares of the business's stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $67.62, for a total value of $47,272,803.90. Following the transaction, the chief executive officer now owns 577,076 shares in the company, valued at approximately $39,021,879.12. This trade represents a 54.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 942,672 shares of company stock worth $64,058,781. 12.30% of the stock is currently owned by company insiders.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.